Stem
Cell Images |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The
target cell for PharmaFrontier's stem cell therapy
is the monocytes. |
The
monocytes are separated from the rest of the blood
cells prior to dedifferentiation |
Dedifferentiated
stem cells (MDSC) can be delivered intravenously. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
These
MDSC can also be differentiated into beta islet cells
and potentially produce insulin. |
These
MDSC can be differentiated into endothelial cells
or myocytes in-situ to help regenerate damaged heart
muscle tissue or myocardium. |
|
|
Tovaxin
Images
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Multiple
sclerosis, or MS is a common debilitating autoimmune
neurological disease where the body's own immune
system attacks normal, healthy tissue because it
sees it as unhealthy tissue. This includes the neurons
that conduct impulses to and from the brain. |
T
cells are the white blood cells that are responsible
for starting this unnecessary immune response, generating
harmful auto-reactive T cells. |
Infiltrations
of auto-reactive T cells along with marcophages and
B cells create a complex autoimmune response. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The
complex autoimmune response, triggered by the auto-reactive
T cells, causes the protective myelin coating, or
myelin sheath, along nerve axons to become inflamed
and eventually destroyed in various places along
the central nervous system. |
When Tovaxin™ (modified,
non-replicating T-cells) are injected subcutaneously
back into the MS patient, they elicit an immune
response against the other harmful T cells that
are degrading the myelin. This greatly reduces
the number of harmful T cells and it is expected
that this vaccine may stop and reverse multiple
sclerosis progression.
|
|
|
|